Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-β neutralizing agent
- 1 April 2001
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 355 (1) , 215-22
- https://doi.org/10.1042/0264-6021:3550215
Abstract
Betaglycan is an accessory receptor of members of the transforming growth factor-beta (TGF-beta) superfamily, which regulates their actions through ligand-dependent interactions with type II receptors. A natural soluble form of betaglycan is found in serum and extracellular matrices. Soluble betaglycan, prepared as a recombinant protein using the baculoviral expression system, inhibits the actions of TGF-beta. Because of its potential use as an anti-TGF-beta therapeutic agent, we have purified and characterized baculoviral recombinant soluble betaglycan. Baculoviral soluble betaglycan is a homodimer formed by two 110 kDa monomers associated by non-covalent interactions. This protein is devoid of glycosaminoglycan chains, although it contains the serine residues, which, in vertebrate cells, are modified by these carbohydrates. On the other hand, mannose-rich carbohydrates account for approximately 20 kDa of the mass of the monomer. End-terminal sequence analysis of the soluble betaglycan showed that Gly(24) is the first residue of the mature protein. Similarly to the natural soluble betaglycan, baculoviral soluble betaglycan has an equilibrium dissociation constant (K(d)) of 3.5 nM for TGF-beta1. Ligand competition assays indicate that the relative affinities of recombinant soluble betaglycan for the TGF-beta isoforms are TGF-beta2>TGF-beta3>TGF-beta1. The anti-TGF-beta potency of recombinant soluble betaglycan in vitro is 10-fold higher for TGF-beta2 than for TGF-beta1. Compared with a commercial pan-specific anti-TGF-beta neutralizing antibody, recombinant soluble betaglycan is more potent against TGF-beta2 and similar against TGF-beta1. These results indicate that baculoviral soluble betaglycan has the biochemical and functional properties that would make it a suitable agent for the treatment of the diseases in which excess TGF-beta plays a central physiopathological role.Keywords
This publication has 48 references indexed in Scilit:
- TGFβ signals through a heteromeric protein kinase receptor complexCell, 1992
- Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney diseaseNature, 1992
- Subtypes of betaglycan and of type I and type II transforming growth factor‐β (TGF‐β) receptors with different affinities for TGF‐β1 and TGF‐β2 are exhibited by human placental trophoblast cellsJournal of Cellular Physiology, 1992
- Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor systemCell, 1991
- The Transforming Growth Factor-beta FamilyAnnual Review of Cell Biology, 1990
- Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoformsJournal of Biological Chemistry, 1990
- Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1Nature, 1990
- The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vectorVirology, 1990
- Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta.The Journal of cell biology, 1989
- DISC ELECTROPHORESIS – II METHOD AND APPLICATION TO HUMAN SERUM PROTEINS*Annals of the New York Academy of Sciences, 1964